CalAmp Corp. CAMP · Stock Open CalAmp Corp. in new tab
CalAmp Corp. Analysis (CAMP)
Is CalAmp Corp. a good investment? CalAmp Corp. (CAMP) is currently trading at 3.84 USD. Market analysts have a consensus price target of 9.92 USD. This suggests a potential upside from current levels.
Earnings Schedule: CalAmp Corp. is expected to release its next earnings report on Aug. 13, 2026. The market consensus estimate for Forward EPS is -0.79.
Investor FAQ
Does CalAmp Corp. pay a dividend?
No, it does not currently pay a dividend.
What asset class is CalAmp Corp.?
CalAmp Corp. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 13, 2026. The company currently has a trailing EPS of -2.31.
Company Profile
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| March 25, 1996 | 2:1 |
Community Discussion